Rujifang inhibits triple-negative breast cancer growth via the PI3K/AKT pathway.
Jia W, Lin X, Chen X, Li H, Zhang X, Zhang Y, Chen Y, Wang B, Chen X, Chen J, Tian H.
Jia W, et al. Among authors: wang b.
J Ethnopharmacol. 2024 Jun 12;327:118011. doi: 10.1016/j.jep.2024.118011. Epub 2024 Mar 10.
J Ethnopharmacol. 2024.
PMID: 38467320
Free article.